Stryker Corporation $SYK Position Lifted by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in Stryker Corporation (NYSE:SYK) by 0.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,157,166 shares of the medical technology company’s stock after buying an additional 2,209 shares during the period. Stryker comprises 3.0% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 8th largest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.30% of Stryker worth $318,672,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. State Street Corp lifted its position in shares of Stryker by 1.2% in the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after purchasing an additional 183,400 shares in the last quarter. Wellington Management Group LLP grew its holdings in Stryker by 0.6% during the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares during the period. Bank of America Corp DE acquired a new position in shares of Stryker during the 2nd quarter worth approximately $1,404,284,000. Royal Bank of Canada increased its holdings in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after buying an additional 481,175 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.2%

Shares of NYSE:SYK opened at $307.65 on Monday. The company has a market capitalization of $118.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 1.98 and a beta of 0.78. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The business’s 50 day simple moving average is $295.23 and its 200 day simple moving average is $311.79.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the company earned $3.13 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on SYK shares. TD Cowen dropped their price target on Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Wells Fargo & Company lowered their price objective on Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 9th. BMO Capital Markets reissued an “outperform” rating and set a $317.00 target price on shares of Stryker in a report on Wednesday, September 9th. Finally, Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $369.00.

Insider Buying and Selling

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.